Wee1 Kinase Assay Kit

Catalog #
79909
$560 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Wee1 Kinase Assay Kit is designed to measure Wee1 kinase activity for screening and profiling applications using Kinase-Glo® Kinase Assay as a detection reagent. The Wee1 Kinase Assay Kit comes in a convenient 96-well format, with enough purified recombinant Wee1 enzyme (amino acids 215-646), Wee1 Substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Need us to run inhibitor screens or profile your compounds against Wee1? Check out our Kinase Screening Services or DNA Replication and Repair Screening Services.

Synonyms
Wee1A Kinase, Wee1 Protein, Wee1-like protein kinase, Wee1A kinase
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • Kinase-Glo® Kinase Assay (Promega #V6071)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator 
Format
Catalog # Name Amount Storage
40412 Wee1, GST-Th-Tag* 15 μg -80°C
79334 5x Kinase Assay Buffer 1 1.5 ml -20°C
79686 500 µM ATP 100 µl -20°C
101574 Wee1 Substrate (5 mg/ml) 200 µl -80°C
79696 White 96-well plate 1 Room
Temp.

*The concentration of the protein is lot-specific and will be indicated on the tube

UniProt #
P30291
Background

Wee1 (also known as WEE1 G2 checkpoint kinase) belongs to the serine-threonine kinase family of proteins. Wee1 plays a crucial role in regulating G2/M transition through phosphorylation of cyclin dependent kinase (CDKs), allowing DNA damage to be repaired. that is overexpressed in many types of cancer such as luminal and HER2-positive breast cancer, hepatocellular carcinomas, and glioblastomas. Classical cancer therapies, such as chemotherapy and radiotherapy, induce DNA damage, and cells trigger the checkpoint in cell cycle, such as Wee1. This can lead to cancer cell resistance. Inhibiting Wee1 prevents cells from repairing DNA damage due to unchecked replication, suggesting that combination therapeutics with DNA damaging reagents and Wee1 inhibitors may be effective against cancer.

References

Parker L., et al., 1992 Science, 257(5078): 1955.
Lundgreen K., et al., 1991 Cell, 64(6): 1111-1122.
Vakili-Samiani S., et al., 2022 Mutat Res 824: 111776.